Results 21 to 30 of about 13,380 (189)
Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre
BMC Nephrology, 2021 Background Gemcitabine is a broadly prescribed chemotherapy, the use of which can be limited by renal adverse events, including thrombotic microangiopathy (TMA). Methods This study evaluated the efficacy of eculizumab, a monoclonal antibody targeting the Maximilien Grall, Florence Daviet, Noémie Jourde Chiche, François Provot, Claire Presne, Jean-Philippe Coindre, Claire Pouteil-Noble, Alexandre Karras, Dominique Guerrot, Arnaud François, Ygal Benhamou, Agnès Veyradier, Véronique Frémeaux-Bacchi, Paul Coppo, Steven Grangé +14 moredoaj +1 more sourceComparison of demographic and outcome in the Brazilian aHUS cohort patients according to the treatment (without the use of Eculizumab, prophylactic Eculizumab, and Eculizumab treatment).
, 2021 Comparison of demographic and outcome in the Brazilian aHUS cohort patients according to the treatment (without the use of Eculizumab, prophylactic Eculizumab, and Eculizumab treatment).Hong Si Nga (4592092), Valter Duro Garcia (5221406), Lilian Monteiro Pereira Palma (4592095), Luis Gustavo Modelli de Andrade (4592089), Roger Kist (7528070), Pedro Augusto Macedo de Souza (11663289), Ida Maria Maximina Fernandes-Charpiot (7586720), Miguel Ernandes Neto (11663283), Silvana Maria Carvalho Miranda (11663286), Gerson Marques Pereira Jr (11663292) +9 morecore +1 more sourceEculizumab hepatotoxicity in pediatric aHUS. [PDF]
, 2015 BACKGROUND
Eculizumab is a humanized anti-C5 antibody approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Its use is increasing in children following reports of its safety and efficacy.Hayes, Wesley, Tschumi, Sibylle, Feber, Janusz, Ling, Simon C, Licht, Christoph, Kirschfink, Michael +5 morecore +2 more sourcesConsistent improvement with eculizumab across muscle groups in myasthenia gravis [PDF]
, 2020 Objective: To assess whether eculizumab, a terminal complement inhibitor, improves patient- and physician-reported outcomes (evaluated using the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale ...Patrick K., McKinnon N., Min J. -H., Koh D. Y., Wang Y., Kurihara R., Kaneko Y., Carnes D., Chaudhry V., Murahara T., Salajegheh M., Beck K., Vidal N., Filla A., Choi M., Alcon K., Frasca V., Samukawa M., Kwon J., Guingrich S., Locheke J., Seok Lee H., Bhavaraju-Sanka R., Goncalves L. O. M., Jeffery D., Agriesti J., Illa I., van der Kooi A., Suzuki H., Amamoto S., Piehl F., Micheels A., Gomes da Silva T. C., Takeyama R., Fukuda Y., Kutlu A., Emmons K., Sakamuri S., Scott T., Novakova I., Herbelin L., Rugiero M., Julia Palacios N., Emilio Alboini P., Yilmaz E., Seddigh A., Motomura M., Fionda L., Gamez Carbonell J., Higuchi E., Marsili Angela, Rocha R., Antonini G., Tsukita K., Andersen H., Sengun I., Szabadosne B., Paula Melo A., Funaka S., Freimer M., Chmelikova M., Schotte C., Camera G., Roe K., Lazaro A., Miller R., Kramer M., Sieren J., Bezerra Rosa B., Eriksson J., Mallon A., Antonio Querol Gutierrez L., McKinnon J., McKenna K., Kikutake K., Alsharabati M., Golden L., Nations S., Sadalage G., Bonanno S., Wolfe G., Eralinna J. -P., Prando N., Sohail F., Loor J., Ugur M., Goyal N., Jacob S., Vandenbussche N., Pasquale A., Lee J., Kawaguchi N., Rojas Garcia R., Ross Berger A., Laaksonen M., Cierny M., Diaz-Manera J., Oksaranta O., Guptill J., Sastre M., Garcia S., Glenn M., Cunningham S., Gollogly J., Di Pasquale A., Carrara F., Matolcsi J., Saito Y., Hietala A., Barroso F., Ra H., Garcia R., de Visser M., Shah A., Phan C., Lee H., Mezache L., Padilla P., Shimpo M., Asada S., Diez Tejedor E., Uwasa K., Cavalcante Lino V., Alam S., Hopkins S., Orsel G., Giacomelli E., Efendi H., Amato A., Sattar N., Sanjak M., Kanzaki A., Taichi N., Maeda Y., Okumura M., Meherremova A., Johns K., de Cassia Santos A., Smetcoren C., Woodall A., Swenson A., Tun O., Brown C., Young Shin H., Carter C., Antozzi C., Mantegazza R., Ishiyama Y., Pinto W., Matsuse D., Gomez Salcedo P., Paula Macagnan A., Bodkin C., Ardoin A., Koga M., Hong Y. -H., Stevens O., Duran G., Tano O., Pinar Acar N., Chaves M., Erdem-Ozdamar S., Veske A., Nakamori M., Pasnoor M., Kissel J., Seelbach J., Goncalves Geraldo J., Sato M., Veiga T., Min Kim S., Konyane M., Schommer C., Iorio R., Hisahara S., Kim M., Eduardo Pazetto L., Vinge L., Zakalik K., Aydinlik S., Marano E., Annes M., Saitoh M., Echevarria L., Nyoung Lee C., Wolfova M., Kamegamori I., Miyawaki E., Seo Koo Y., Costabile T., Casasnovas C., Ahn S. -H., Dogan B., Kawamura T., Marburger T., Yoshimura S., Vanhee A., Kazim Onar M., Van Daele S., Nagane Y., Welsh L., Kelley A., Kohlrus S., So Y. T., Darnell T., da Penha Ananias Morita M., Tsuda E., Gutmann L., Pitha J., Utsugisawa K., Lovas G., Muharrem F., Kobashikawa T., Friedrich M. A. G., Watling D., Engel M., Chelnick S., Joon Kim B., Mumfrey-Thomas S., Nakamura Y., Barohn R., Guerreiro A., Muppidi S., Nam Kang H., Juel V., McVey A., Minton B., Martins Ribeiro R., Bi Hwang E., Szabo G., Scala S., Jurajdova I., Garibaldi M., Jakab G., Park S., Fernandes P., Haar L., Kanai T., Aranke S., Nogueira Coelho E., Van den Abeele G., Troili F., Chad Hoyle J., Sokratous G., Bravver E., Gonzalez A., Mahdi-Rogers M., Torres D. D. M., Paulose S., da Cruz Pacheco D., Futono K., Srinivasan J., Campanella A., Cash T., Morino S., Kaur H., Jeong H. -N., Cesar P., Jung J., Dimitrova D., Yamashita Y., Souza Duca L., Mahieu D., Khoury J., Norwood F., Ferreira L., Hasuike T., Ventura N., Ho D., Forshew D., Fasanaro A., Tobon Gonzalez A., Vynckier J., Corse A., Walsh M., Takahashi M., Dimachkie M., Torane P., Tsuda T., Jenci N., Arndt H., Shabbir Y., Dezsi L., Gibson T., Filla Alessandro, Suzuki Y., Mosmiller B., Shimohama S., Tuga C., Ozawa Y., Becerikli G., Youl Seok H., Sano Y., Masaki K., O'Brien F. L., Cochrane T., Reguliova K., Murai H., Renata Cubas Volpe L., Silvestri N., Zilliox L., Yoshida S., Jerath N., Davies D., Junkerova J., Harbo T., Horvath M., Pineda C., Bettini M., Amaral de Andrade A. C., Dalila Garcia A., Balkan B., Ishiyama N., Terzi M., de Koning K., Souza I., Mori M., Velez Santamaria V., Cortes Vicente E., Ye Hwang J., Snook R., Rosenfeld J., Suzuki S., Liu T., Antonia Alberti Aguilo M., Vytopil M., Dias Brockhausen I., Saklad A., Feder D., Augusto Suriane Fialho T., Young V., Onesti E., Diez Porras L., Statland J., Karam C., Miranda C., Fernanda Butinhao C., Howard J. F., Donahue C., Brooks B., Kurkova B., Weiner E., Mette Ostergaard Autzen A., Sacca F., Toncrova S., Kim B. -J., Witting N., Amato K., Katz J., Fujii Y., Caliskan Y., Yasuda I., Mathew V., Ozcelik P., Semiz C., Dishman L., Kawamata J., Mogensen A., Burdette M., Zapletalova O., Marsili A., Ambrosio D., Depreitere A., Hayashi T., Inghilleri M., Toska S., Kim Y. -H., Locatelli A., Shin M., Wilken M., Siddiqi Z., Won Shin C., Herbert C., Agrawal B., Kazamel M., Duarte Silva L., Lopergolo D., Elsayed M., Pinto G., Kincaid J., Bjarbo L., Watt E., Massey J., Sune P., Lopez Ruiz P., Hobson-Webb L., Jones F., Narayan J., Saccà Francesco, Takada K., Jara J., Lokaitis B., Plevka S., Lim Koo D., Akiyama T., Souza Bulle Oliveira A., Gabriele M., Fondaw A., Yamamoto D., Kamakura S., Silva M., Assis N., Saba J., Pasanisi M., Daniels K., Kobayashi E., Matsushita T., Kirbas Cavdar T., Pulley M., Shiraishi H., Pereira Martins M., Lu L., Rozsa C., Mizugami A., Homedes-Pedret C., Gabriel Mazia C., Takada M., Alves de Siqueira Carvalho A., D'Amato V., Smith L., Callison K., Vohanka S., Trivedi J., Jingu M., Nance C., Mukaino A., James Jones H., Fernandez-Fournier M., Mozaffar T., Pascuzzi R., Hafer-Macko C., Wagemaekers L., Kobayashi H., Maqsood F., Noshiro M., Rico G., De Mey K., Paiva G., Maggi L., Yountz M., Morikawa M., Osakada K., Imai T., Gili G., Nemeth J., Sathasivam S., Haw Choi E., Olalde H., Varga E., Rodriguez de Rivera F. J., Meguro F., DiSanzo B., Mohr H., Tyblova M., Bednarik J., Verjans S., Nozaki K., Miyazaki T., Lim J. -S., Gori M., Mazuela G., Anderson A., De Bleecker J., Salvado Figueras M., Blackmore D., Gilchrist J., Harrison T., Vidal G., Pozo M., Shah J., Pedersen J., Evoli A., Krogh S., Tsurumaru M., Uzawa A., Cavus H., Dimitriou A., Hojgaard J., Van Damme P., Pol S., Roderus R., Bekircan-Kurt C., Maier G., Puorro G., Tilkin P., Kressin N., Vecsei L., Kwan J., Narikawa K., Roy G., Mercelis R., Varghese M., Vissing J., Arribas-Ibar E., Puorro Giorgia, Uehara T., Bin Cho E., D'Hont A., Augusto da Silva L., Santos Engel M., Seok J., Sen S. +501 morecore +5 more sourcesAplicaciones terapéuticas del eculizumab [PDF]
, 2022 Introducción: El eculizumab es un anticuerpo monoclonal de tipo IgG diseñado para el tratamiento de la hemoglobinuria paroxística nocturna (HPN), en el que su diana farmacológica forma parte del sistema del complemento.Campos González, Natalia, Chacón-Jiménez, Luz, Ruiz Jiménez, Susana, Rodríguez-Jiménez, Johanna, Chacón Jiménez, Luz María, Ruiz-Jiménez, Susana, Rodríguez Jiménez, Johanna, Campos-González, Natalia, Johanna Rodríguez-Jiménez, Natalia Campos-González, Luz Chacón-Jiménez, Susana Ruiz-Jiménez +11 morecore +1 more sourceAtypical haemolytic uraemic syndrome in the eculizumab era: presentation, response to treatment and evaluation of an eculizumab withdrawal strategy [PDF]
, 2019 The complement inhibitor, eculizumab, has revolutionised the management of atypical haemolytic uraemic syndrome (aHUS), although the optimum treatment duration is debated.Shah, R, Scully, M, Neave, L, Gale, DP, Cheesman, S +4 morecore +2 more sourcesEculizumab in Pediatric Kidney Disorders: A Review: Eculizumab in Kidney Disorders
, 2022 Eculizumab is a humanized monoclonal antibody targeting the C5 (complement 5) memberof complement proteins and inhibiting its cleavage to C5a and C5b. Eculizumab has beenproven to be effective in a wide array of nephrologic, neurologic, and hematologic ...Mohkam, Masoumeh, Akhondi, Amir Hossein, Kamali, Farnaz, Jamee, Mahnaz, Hajialigol, Amir Hossein, Farsi, Yeganeh, Mirzaee, Mahbubeh +6 morecore +1 more sourceCase Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient
Frontiers in Immunology, 2021 BackgroundWith the introduction of eculizumab, a C5-inhibitor, morbidity and mortality improved significantly for patients with atypical hemolytic uremic syndrome (aHUS).Romy N. Bouwmeester, Mendy Ter Avest, Kioa L. Wijnsma, Caroline Duineveld, Rob ter Heine, Elena B. Volokhina, Lambertus P. W. J. Van Den Heuvel, Jack F. M. Wetzels, Nicole C. A. J. van de Kar +8 moredoaj +1 more sourceEculizumab dosing in infants
Indian Journal of Nephrology, 2018 Eculizumab is the therapy of choice for patients with atypical hemolytic uremic syndrome (aHUS). Dosing recommendations stem from two trials: one retrospective trial (19 children and 5 infants) and one prospective trial (22 patients and 5 infants). This case report highlights the need for more precise dosing recommendations in children, particularly in Kobrzynski, M, Wile, B, Huang, S S, Filler, G +3 moreopenaire +3 more sources
